Literature DB >> 22688071

Surgical treatment of moyamoya disease in adults: combined direct and indirect vs. indirect bypass surgery.

Dal-Soo Kim1, Pil-Woo Huh, Hyung-Seok Kim, In-Soo Kim, Seokmin Choi, Jin-Ho Mok, Choon-Woong Huh.   

Abstract

Combined superficial temporal artery-middle cerebral artery anastomosis and encephalo-duro-arterio-galeo-synangiosis (EDAGS) were retrospectively compared with indirect bypass, EDAGS with or without inversion, in 134 hemispheres of 96 adult patients with non-hemorrhagic moyamoya disease (MMD) in terms of angiographic findings, perioperative complications, and clinical outcome. Angiographic revascularization seemed to be better in the combined bypass group compared with the EDAGS group (p = 0.045), but perioperative complication tended to be slightly more common in the combined bypass group. No statistical differences were found in clinical outcome. EDAGS is a very reliable alternative to combined bypass in adult MMD. However, randomized clinical trials are needed to assess the long-term efficacy of any bypass surgery in adult patients with MMD.

Entities:  

Mesh:

Year:  2012        PMID: 22688071     DOI: 10.2176/nmc.52.333

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  10 in total

Review 1.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 2.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

3.  Clinical and angiographic outcomes after combined direct and indirect bypass in adult patients with moyamoya disease: A retrospective study of 76 procedures.

Authors:  Jinbing Zhao; Hongyi Liu; Yuanjie Zou; Wenbin Zhang; Shengxue He
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

4.  Multiple encephalogaleoperiosteal synangiosis for bilateral carotid artery stenosis in a 13-year-old girl: a case report.

Authors:  Akinori Inamura; Sadahiro Nomura; Hirokazu Sadahiro; Takayuki Oku; Hideyuki Ishihara; Michiyasu Suzuki
Journal:  Childs Nerv Syst       Date:  2015-09-26       Impact factor: 1.475

5.  Encephaloduroarteriosynangiosis Averts Stroke in Atherosclerotic Patients With Border-Zone Infarct: Post Hoc Analysis From a Performance Criterion Phase II Trial.

Authors:  Miguel D Quintero-Consuegra; Juan F Toscano; Robin Babadjouni; Peyton Nisson; Mohammad N Kayyali; Daniel Chang; Eyad Almallouhi; Jeffrey L Saver; Nestor R Gonzalez
Journal:  Neurosurgery       Date:  2021-03-15       Impact factor: 4.654

Review 6.  A Recent Update of Clinical and Research Topics Concerning Adult Moyamoya Disease.

Authors:  Jin Pyeong Jeon; Jeong Eun Kim
Journal:  J Korean Neurosurg Soc       Date:  2016-10-24

Review 7.  Surgical techniques and indications for treatment of adult moyamoya disease.

Authors:  Vincent N Nguyen; Kara A Parikh; Mustafa Motiwala; L Erin Miller; Michael Barats; Camille Milton; Nickalus R Khan
Journal:  Front Surg       Date:  2022-08-19

8.  Resolution of bilateral moyamoya associated collateral vessel aneurysms: Rationale for endovascular versus surgical intervention.

Authors:  Sepideh Amin-Hanjani; Sean Goodin; Fady T Charbel; Ali Alaraj
Journal:  Surg Neurol Int       Date:  2014-06-19

9.  The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis.

Authors:  Cong Qian; Xiaobo Yu; Jianru Li; Jingyin Chen; Lin Wang; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  A meta-analysis of comparisons of various surgical treatments for moyamoya diseases.

Authors:  Kai Lin; Shaohua Sui; Jing Zhao; Liyong Zhang; Kun Chen
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.